📣 VC round data is live. Check it out!

Pacific Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Pacific Biosciences and similar public comparables like OmniAb, Myriad Genetics, SOPHiA Genetics, Nautilus Biotechnology and more.

Pacific Biosciences Overview

About Pacific Biosciences

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.


Founded

2000

HQ

United States

Employees

575

Website

pacb.com

Financials (LTM)

Revenue: $163M
EBITDA: ($141M)

EV

$785M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Pacific Biosciences Financials

Pacific Biosciences reported last 12-month revenue of $163M and negative EBITDA of ($141M).

In the same LTM period, Pacific Biosciences generated $54M in gross profit, ($141M) in EBITDA losses, and had net loss of ($389M).

Revenue (LTM)


Pacific Biosciences P&L

In the most recent fiscal year, Pacific Biosciences reported revenue of $160M and EBITDA of ($153M).

Pacific Biosciences is unprofitable as of last fiscal year, with gross margin of 29%, EBITDA margin of (95%), and net margin of (341%).

See analyst estimates for Pacific Biosciences
LTMLast FY202320242025202620272028
Revenue$163M$160M$201M$154M$160M
Gross Profit$54M$46M$53M$37M$46M
Gross Margin33%29%26%24%29%
EBITDA($141M)($153M)($277M)($243M)($153M)
EBITDA Margin(86%)(95%)(138%)(158%)(95%)
EBIT Margin(103%)(111%)(155%)(189%)(348%)
Net Profit($389M)($546M)($307M)($310M)($546M)
Net Margin(238%)(341%)(153%)(201%)(341%)
Net Debt—$582M———

Financial data powered by Morningstar, Inc.

Pacific Biosciences Stock Performance

Pacific Biosciences has current market cap of $357M, and enterprise value of $785M.

Market Cap Evolution


Pacific Biosciences' stock price is $1.15.

Pacific Biosciences share price decreased by 27.7% in the last 30 days, and increased by 19.3% in the last year.

Pacific Biosciences has an EPS (earnings per share) of $-1.76.

See more trading valuation data for Pacific Biosciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$785M$357M0.0%-27.7%-31.5%19.3%$-1.76

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Pacific Biosciences Valuation Multiples

Pacific Biosciences trades at 4.8x EV/Revenue multiple, and (5.6x) EV/EBITDA.

See NTM and 2027E valuation multiples for Pacific Biosciences

EV / Revenue (LTM)


Pacific Biosciences Financial Valuation Multiples

As of May 20, 2026, Pacific Biosciences has market cap of $357M and EV of $785M.

Pacific Biosciences has a P/E ratio of (0.9x).

LTMLast FY202320242025202620272028
EV/Revenue4.8x4.9x3.9x5.1x4.9x
EV/EBITDA(5.6x)(5.1x)(2.8x)(3.2x)(5.1x)
EV/EBIT(4.6x)(4.4x)(2.5x)(2.7x)(1.4x)
EV/Gross Profit14.5x17.1x14.9x21.0x17.1x
P/E(0.9x)(0.7x)(1.2x)(1.2x)(0.7x)
EV/FCF—(6.6x)(2.9x)(3.7x)(6.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Pacific Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Pacific Biosciences Margins & Growth Rates

Pacific Biosciences grew revenue by 5% but EBITDA decreased by 32% in the last fiscal year.

In the most recent fiscal year, Pacific Biosciences reported gross margin of 29%, EBITDA margin of (95%), and net margin of (341%).

See estimated margins and future growth rates for Pacific Biosciences

Pacific Biosciences Margins

Last FY202420252026202720282029
Gross Margin29%24%29%39%
EBITDA Margin(95%)(158%)(95%)(62%)
EBIT Margin(111%)(189%)(348%)(92%)
Net Margin(341%)(201%)(341%)(81%)
FCF Margin(74%)(138%)(74%)—

Pacific Biosciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth5%(23%)4%5%
Gross Profit Growth42%(29%)23%42%
EBITDA Growth(32%)(12%)(37%)(32%)
EBIT Growth(12%)(6%)92%(72%)
Net Profit Growth(75%)1%76%(75%)
FCF Growth—(21%)(44%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

Pacific Biosciences Operational KPIs

Pacific Biosciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.0M for the same period.

Pacific Biosciences' Rule of 40 is (56%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pacific Biosciences' Rule of X is (49%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Pacific Biosciences
LTMLast FY202320242025202620272028
Rule of 40(78%)(56%)———
Bessemer Rule of X(64%)(49%)———
Revenue per Employee—$0.3M———
Opex per Employee—$1.0M———
R&D Expenses to Revenue57%61%93%88%61%
Opex to Revenue—377%181%213%377%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Pacific Biosciences Competitors

Pacific Biosciences competitors include OmniAb, Myriad Genetics, SOPHiA Genetics, Nautilus Biotechnology, ToolGen, Fulgent Genetics, Prenetics Global, Abclon, Mirxes Holding and Atrys Health.

Most Pacific Biosciences public comparables operate across Diagnostics & Genomics, Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
OmniAb16.8x13.5x(7.0x)(7.7x)
Myriad Genetics0.5x0.5x10.9x11.0x
SOPHiA Genetics4.3x4.0x(8.0x)(8.7x)
Nautilus Biotechnology—867.5x(3.9x)(3.6x)
ToolGen473.6x—(18.2x)—
Fulgent Genetics0.6x0.6x(18.7x)(6.8x)
Prenetics Global2.0x1.4x(14.3x)(12.2x)
Abclon140.1x—(40.4x)—

This data is available for Pro users. Sign up to see all Pacific Biosciences competitors and their valuation data.

Start Free Trial

Pacific Biosciences M&A Activity

Pacific Biosciences has acquired 3 companies to date.

Last acquisition by Pacific Biosciences was on August 2nd 2023. Pacific Biosciences acquired Apton Biosystems for $110M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Pacific Biosciences

Apton Biosystems
Circulomics
Omniome
Description
Apton Biosystems is a California-based developer of super-resolution optical systems for DNA sequencing and protein detection at sub-wavelength scales. The technology supports biomarker discovery, early disease diagnostics, and therapeutic monitoring, advancing precision medicine applications in research labs worldwide.
Circulomics is a Baltimore-based biotech firm developing kits for long-read sequencing sample preparation and microRNA analysis. Located in IMET's incubator, it has secured $8 million from NIH and TEDCO grants. Products like NanoMotor kits enable single-molecule nucleic acid handling for genomics research and diagnostics. Founded in 2007, Circulomics supplies tools to labs worldwide for biomarker discovery.
—
HQ CountryUnited StatesUnited StatesUnited States
HQ City
San Francisco, CA
Baltimore, MD
—
Deal Date2 Aug 20233 Aug 202120 Jul 2021
Valuation$110M$30M$800M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Pacific Biosciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Pacific Biosciences

When was Pacific Biosciences founded?Pacific Biosciences was founded in 2000.
Where is Pacific Biosciences headquartered?Pacific Biosciences is headquartered in United States.
How many employees does Pacific Biosciences have?As of today, Pacific Biosciences has over 575 employees.
Who is the CEO of Pacific Biosciences?Pacific Biosciences' CEO is Christian O. Henry.
Is Pacific Biosciences publicly listed?Yes, Pacific Biosciences is a public company listed on Nasdaq.
What is the stock symbol of Pacific Biosciences?Pacific Biosciences trades under PACB ticker.
When did Pacific Biosciences go public?Pacific Biosciences went public in 2010.
Who are competitors of Pacific Biosciences?Pacific Biosciences main competitors include OmniAb, Myriad Genetics, SOPHiA Genetics, Nautilus Biotechnology, ToolGen, Fulgent Genetics, Prenetics Global, Abclon, Mirxes Holding, Atrys Health.
What is the current market cap of Pacific Biosciences?Pacific Biosciences' current market cap is $357M.
What is the current revenue of Pacific Biosciences?Pacific Biosciences' last 12 months revenue is $163M.
What is the current revenue growth of Pacific Biosciences?Pacific Biosciences revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Pacific Biosciences?Current revenue multiple of Pacific Biosciences is 4.8x.
Is Pacific Biosciences profitable?No, Pacific Biosciences is not profitable.
What is the current EBITDA of Pacific Biosciences?Pacific Biosciences has negative EBITDA and is not profitable.
What is Pacific Biosciences' EBITDA margin?Pacific Biosciences' last 12 months EBITDA margin is (86%).
What is the current EV/EBITDA multiple of Pacific Biosciences?Current EBITDA multiple of Pacific Biosciences is (5.6x).
How many companies Pacific Biosciences has acquired to date?As of May 2026, Pacific Biosciences has acquired 3 companies.
What was the largest acquisition by Pacific Biosciences?$800M acquisition of Omniome on 20th July 2021 was the largest M&A Pacific Biosciences has done to date.
What companies Pacific Biosciences acquired?Pacific Biosciences acquired Omniome, Apton Biosystems, and Circulomics.
In how many companies Pacific Biosciences has invested to date?Pacific Biosciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Pacific Biosciences

Lists including Pacific Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial